AATF is Overexpressed in Human Head and Neck Squamous Cell Carcinoma and Regulates STAT3/Survivin Signaling

Lin Fu1,2, Quanxiu Jin3, Qianze Dong1,2

  • 1Department of Pathology, College of Basic Medical Science, China Medical University, Shenyang, People's Republic of China.

Oncotargets and Therapy
|November 17, 2021
PubMed
Abstract

Insights

Apoptosis antagonizing transcription factor (AATF) is elevated in head and neck squamous cell carcinoma (HNSCC), promoting cisplatin resistance and reducing apoptosis. Targeting AATF may offer a new therapeutic strategy for HNSCC patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Dysregulation of apoptosis antagonizing transcription factor (AATF) is linked to various cancers.
  • The role of AATF in human head and neck squamous cell carcinoma (HNSCC) requires further investigation.

Purpose of the Study:

  • To investigate the expression patterns of AATF in HNSCC.
  • To elucidate the biological functions and underlying mechanisms of AATF in HNSCC progression and treatment response.

Main Methods:

  • Immunohistochemistry on 119 HNSCC samples.
  • Cell proliferation, apoptosis assays (CCK-8, colony formation, Annexin V/PI), Western blotting, and RNA-sequencing.
  • Analysis of TCGA and Oncomine databases for AATF expression and correlation with patient survival.

Main Results:

  • AATF expression is upregulated in HNSCC tissues and correlates with advanced stage and poorer survival.
  • AATF overexpression enhances cell growth, colony formation, and cisplatin resistance, while reducing apoptosis.
  • AATF regulates STAT3/survivin signaling pathway, influencing apoptosis and chemoresistance.

Conclusions:

  • AATF is overexpressed in HNSCC and promotes cisplatin resistance and reduced apoptosis.
  • The STAT3/survivin signaling pathway is implicated in AATF's function.
  • AATF represents a potential therapeutic target for HNSCC treatment.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.7K
Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
5.2K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.2K